9 METERS BIOPHARMA, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2017 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
9 Meters Biopharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2017 to Q1 2023.
  • 9 Meters Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2023 was $737K, a 6.81% increase year-over-year.
  • 9 Meters Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2023 was $3.99M, a 48.6% increase year-over-year.
  • 9 Meters Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.94M, a 63.2% increase from 2021.
  • 9 Meters Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.41M, a 48.9% decline from 2020.
  • 9 Meters Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $4.72M, a 64.5% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $3.99M $737K +$47K +6.81% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $3.94M $744K +$215K +40.6% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-28
Q3 2022 $3.72M $730K +$205K +39% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $3.52M $1.77M +$837K +89.3% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $2.68M $690K +$268K +63.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $2.41M $529K +$305K +136% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 $2.11M $525K +$323K +160% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $1.79M $937K -$3.08M -76.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $4.87M $422K +$146K +52.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $4.72M $224K -$369K -62.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-23
Q3 2020 $5.09M $202K -$698K -77.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $5.79M $4.02M +$3.17M +372% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $2.62M $276K -$250K -47.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $2.87M $593K +$647K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-22
Q3 2019 $2.22M $900K +$4.03M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$1.81M $852K +$1.04M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$2.84M $526K -$6.65M -92.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $3.81M -$54K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-20
Q3 2018 -$3.13M -$4.41M -345% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$184K -$1.27M -117% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $7.17M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q3 2017 $1.28M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $1.09M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.